Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment strategy to assure the company’s impressive growth. Furthermore, he surveys the Polish R&D landscape and discusses the importance of a strong connection between academia and industry to kick-start the domestic biotech scene.
Celon Pharma received an award for the highest initial public offering (IPO) value on the Warsaw stock exchange in 2016. What was the key factor for such a successful IPO?
"There is an overwhelming need in Poland for well-structured and positioned R&D companies with balanced risk run by people with a successful track record – such as Celon Pharma."
